United Therapeutics (UTHR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
The meeting was held virtually on the company's 30th anniversary, with introductions of key executives and board members present online.
The agenda and rules of conduct were made available on the virtual meeting website, with instructions for participation and technical contingencies.
Board and executive committee updates
All 12 director nominees were introduced for election to serve one-year terms until the next annual meeting.
Key board members and committee chairs were present, including the Lead Independent Director and Nominating and Governance Committee Chair.
Shareholder proposals
Four proposals were presented for voting: election of directors, advisory approval of executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of the independent auditor.
The board recommended voting in favor of all nominees and proposals.
Latest events from United Therapeutics
- Q2 2026 revenues fell 2% to $783.3M, but net income rose 8% to $333M on Tyvaso DPI growth.UTHR
Q2 2026 - Record growth, breakthrough pulmonary fibrosis results, and pioneering xenotransplantation trials.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum - Ralinepag and Tyvaso advances drive growth, with innovation and new markets fueling future expansion.UTHR
TD Cowen 46th Annual Health Care Conference - Strong clinical results and pipeline advances underpin ambitious growth targets through 2027.UTHR
Jefferies Global Healthcare Conference 2026 - Ralinepag reduced clinical worsening in PAH by 55% with robust efficacy and safety.UTHR
Study result - TETON-2 showed significant FVC improvement and robust efficacy for nebulized Tyvaso in IPF.UTHR
Study Update - Landmark TETON-2 results drive IPF expansion, $1B buyback, and xenotransplant pipeline progress.UTHR
Morgan Stanley 23rd Annual Global Healthcare Conference - Q2 2025 revenue up 12% to $799M, with strong Tyvaso DPI growth and $1B buyback approved.UTHR
Q2 2025 - Q2 2024 revenue up 20% to $715M, net income $278.1M, Tyvaso led growth, $1B buyback completed.UTHR
Q2 2024